Readily available, high throughput tests that can detect the extent of cerebral Aβ plaques and tau pathology using positron emission tomography (PET) and/or cerebrospinal fluid (CSF) have been demonstrated to be effective tools in the clinical trial setting for identification of individuals with AD pathology. Here, MAPT is linked to Alzheimer disease.